Development of novel drugs for human African trypanosomiasis-Reference-Cited by-同舟云学术

Development of novel drugs for human African trypanosomiasis

Published:2011-06 Issue:6 Volume:6 Page:677-691
ISSN:1746-0913
Container-title:Future Microbiology
language:en
Short-container-title:Future Microbiology

Author:

Brun Reto¹,Don Robert²,Jacobs Robert T³,Wang Michael Zhuo⁴,Barrett Michael P⁵

Affiliation:

1. Department Medical Parasitology & Infection Biology, Swiss Tropical & Public Health Institute, and, University of Basel, CH-4002 Basel, Switzerland.

2. Drugs for Neglected Diseases initiative, Geneva, Switzerland

3. Department of Chemistry, SCYNEXIS, Inc., PO Box 12878, Research Triangle Park, NC, 27709-2878, USA

4. Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA

5. Wellcome Trust Centre for Molecular Parasitology, University of Glasgow, Glasgow, Scotland

Abstract

Human African trypanosomiasis (HAT) or ‘sleeping sickness’ is a neglected tropical disease caused by the parasite Trypanosoma brucei. Novel models for funding pharmaceutical development against HAT are beginning to yield results. The Drugs for Neglected Diseases initiative (DNDi) rediscovered a nitroimidazole, fexinidazole, which is currently in Phase I clinical trials. Novel benzoxaboroles, discovered by Anacor, Scynexis and DNDi, have good pharmacokinetic properties in plasma and in the brain and are curative in a murine model of stage two HAT with brain infection. The Consortium for Parasitic Drug Development (CPDD) has identified a series of dicationic compounds that can cure a monkey model of stage two HAT. With other screening programs yielding hits, the pipeline for new HAT drugs might finally begin to fill.

Publisher

Future Medicine Ltd

Subject

Microbiology (medical),Microbiology

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fmb.11.44

Reference72 articles.

1. Human African trypanosomiasis

2. Kinetoplastids: related protozoan pathogens, different diseases

3. Human African trypanosomiasis: pharmacological re-engagement with a neglected disease

4. The Natural Progression of Gambiense Sleeping Sickness: What Is the Evidence?

5. The trypanolytic factor of human serum: many ways to enter the parasite, a single way to kill

Cited by 119 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Key Contributions by the Swiss Tropical and Public Health Institute Towards New and Better Drugs for Tropical Diseases;CHIMIA;2023-09-20

2. In vitro anti‐trypanosomal activity of synthetic nitrofurantoin‐triazole hybrids against Trypanosoma species causing human African trypanosomosis;Fundamental & Clinical Pharmacology;2023-07-21

3. Development of a 2,4-Diaminothiazole Series for the Treatment of Human African Trypanosomiasis Highlights the Importance of Static–Cidal Screening of Analogues;Journal of Medicinal Chemistry;2023-06-21

4. The pipeline for drugs for control and elimination of neglected tropical diseases: 1. Anti-infective drugs for regulatory registration;Parasites & Vectors;2023-03-01

5. Structure-activity relationship of dibenzylideneacetone analogs against the neglected disease pathogen, Trypanosoma brucei;Bioorganic & Medicinal Chemistry Letters;2023-02